Dr Chloë G. K. Atkins joins Ethics Talk to discuss her article, coauthored with Dr Sunit Das: “What Should Clinicians and Patients Know About the Clinical Gaze, Disability, and Iatrogenic Harm When Making Decisions?”
AMA Journal of Ethics theme editor Subha Perni, MD, a recent graduate of the Columbia University College of Physicians and Surgeons, interviewed Elizabeth Epstein, PhD, RN, about strategies for understanding and address moral distress in clinical settings.
As billable procedures, advance care planning (ACP) conversations need measurable outcomes and training support. Integrating ACP into standard practice is key to ensuring clinicians deliver care that matters to patients.
AMA J Ethics. 2018;20(8):E750-756. doi:
10.1001/amajethics.2018.750.
Pathologists should work cooperatively with clinicians and provide guidance about appropriate testing to uphold the medical ethics principle of justice.
AMA J Ethics. 2016;18(8):793-799. doi:
10.1001/journalofethics.2016.18.8.ecas5-1608.
Joel A. DeLisa, MD, MS and Jacob Jay Lindenthal, PhD, DrPH
Research on experiences of practicing physicians who have disabilities could help medical schools counsel applicants and increase enrollment among students with disabilities. This can ultimately improve care for patients with disabilities.
AMA J Ethics. 2016;18(10):1003-1009. doi:
10.1001/journalofethics.2016.18.10.stas1-1610.
Lyubov Slashcheva, Rick Rader, MD, and Stephen B. Sulkes, MD
Designation of people with intellectual and developmental disabilities as a medically underserved population would not solve problems of access to care.
AMA J Ethics. 2016;18(4):422-429. doi:
10.1001/journalofethics.2016.18.4.pfor1-1604.
To make good communication choices for their children who are deaf or hard of hearing, hearing parents must develop their understanding of hearing loss.
AMA J Ethics. 2016;18(4):442-446. doi:
10.1001/journalofethics.2016.18.4.sect1-1604.
Defining typical appearance as a goal of health service provision is harmful and unnecessary for traits that are stigmatized but neither harmful nor distressing.
AMA J Ethics. 2021;23(7):E569-575. doi:
10.1001/amajethics.2021.569.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.